Management of Patients with Her2+ve Brain metastases Her2+ve - - PowerPoint PPT Presentation

▶
management of patients with her2 ve brain metastases
SMART_READER_LITE
LIVE PREVIEW

Management of Patients with Her2+ve Brain metastases Her2+ve - - PowerPoint PPT Presentation

Mar 07, 2024 391 likes •586 views

Management of Patients with Her2+ve Brain metastases Her2+ve patients 15% of all breast cancer Even with adjuvant trastuzumab 10-15% relapse Trastuzumab does not cross BBB Management dependent on number of metastases Patients

slide-1
SLIDE 1

Management of Patients with Her2+ve Brain metastases

  • Her2+ve patients 15% of all breast cancer
  • Even with adjuvant trastuzumab 10-15% relapse
  • Trastuzumab does not cross BBB
  • Management dependent on number of metastases
  • Patients should be closely followed up
slide-2
SLIDE 2
  • Patients can have a better prognosis
  • Important to control systemic and brain disease
  • Management of patients must be multidisciplinary
  • Case studies

Management of Patients with Her2+ve Brain metastases

slide-3
SLIDE 3

Basal ER - Her 2 - Luminal A ER + Her 2- Her2 ER - Her2 + Luminal B ER + Her2 +

Breast GPA graded prognostic assessment

Sperduto Red J

  • urnal 2012 82(5)
slide-4
SLIDE 4

NHSCB/D5/1 guidance on SRS/SRBT

–MDT; local, neuro, stereotactic –PS KPS>70 –Diagnosis of cancer established and absent or controllable primary disease –No pressure symptoms (or surgery) –Pre treatment scans vol <20cc (<3cm)** –Life expectancy from extracranial disease >6months

  • Treat new lesions - >3months and above
  • Retreat lesions - >6 months and above
slide-5
SLIDE 5

Case presentation 1

LR 31.1.63 42 at diagnosis. CA Lt Brst. Lt WLE +ANC J une 2005 T1(18) N0 G3 ER+ HER2+ Nov10: Liver lung Ophthalmic and Bone mets. Feb’12 : Brain mets-widespread. Given WBRT Apr’12: 4cm mediastinal mass. Pamidronate xeloda lapatinib.

slide-6
SLIDE 6

Case presentation 1

Aug’12: Scanning PR mediastinum and brain. Oct’12: Chemo break due to side effects Feb’13: Progressive liver mets. Stable brain mets. TDM -1 trial Oct ’13: CR liver and excellent PR brain.

slide-7
SLIDE 7
slide-8
SLIDE 8

13/ 2/ 12 diagnosis 14/ 4/ 12 post WBRT 14/ 8/ 12 4/ 12 X+L 1/ 10/ 12 Chemo break 18/ 2/ 13 Start TDM -1

slide-9
SLIDE 9

Feb 2013 Oct 2013

slide-10
SLIDE 10

Case presentation 2

KS 17.6.77 33 at diagnosis CA Rt Brst. M asty +ANC Nov 2010 T2 N3 G3 ER+ HER2+ Apr’12: Headaches – oligomets. No visceral mets. Excision Rt cerebellar met. WBRT 30Gy/ 10fractions-PR Options gamma knife or alternative HER2 therapy. Xeloda lapatinib given to shrink mets. Sept’12 PR. Nov’12: increased Lt frontal & parietal lesions. Gamma knife

slide-11
SLIDE 11
slide-12
SLIDE 12
slide-13
SLIDE 13
slide-14
SLIDE 14

4/ 4/ 12 diagnosis 23/ 5/ 12 Post WBRT 28/ 8/ 12 3/ 12 X+L 21/ 11/ 12 6/ 12 X+L 4/ 2/ 13

Post ɣ knife

slide-15
SLIDE 15
  • April ’13 progression left frontal lobe metastasis &

new right cerebellar lesion

  • Excision left frontal metastasis May 2013
  • Gamma knife cerebellar lesion June 2013
  • MRI Sept 2013 no progression. No visceral mets.

Case presentation 2

slide-16
SLIDE 16

4/ 2/ 13

Post ɣ knife

23/ 4/ 13 progression 12/ 9/ 13 post

excision & ɣ knife

slide-17
SLIDE 17

Brain metastases cases

Discuss options in specialist MDT Follow pts and treat appropriately just as we do with their systemic disease Patients may well live for many months or years with appropriate therapy